About Fractyl laboratories inc.
Fractyl Laboratories Inc. is a biotechnology company that is dedicated to developing innovative treatments for type 2 diabetes. The company's focus is on regulating the body's metabolic controller, the duodenum, which plays a crucial role in glucose metabolism.
The duodenum is the first part of the small intestine and it plays an important role in regulating blood sugar levels. When food enters the duodenum, it triggers the release of hormones that signal to the pancreas to produce insulin. Insulin helps to transport glucose from the bloodstream into cells where it can be used for energy.
However, in people with type 2 diabetes, this process doesn't work properly. The duodenum becomes less sensitive to these hormonal signals and as a result, insulin production decreases and blood sugar levels rise.
Fractyl Laboratories Inc.'s approach involves using an endoscopic procedure called Revita DMR (duodenal mucosal resurfacing) to treat patients with type 2 diabetes. During this procedure, a catheter is inserted through the mouth and into the small intestine where radiofrequency energy is used to resurface or ablate specific areas of tissue within the lining of the duodenum.
This process stimulates regeneration of healthy tissue which restores sensitivity to hormonal signals and improves insulin production leading ultimately towards better control over blood sugar levels.
Revita DMR has been shown in clinical trials conducted by Fractyl Laboratories Inc., as well as other independent studies around world that it can significantly improve glycemic control in patients with type 2 diabetes without requiring any medication or surgery.
The treatment has also been shown to have long-lasting effects on glycemic control even after several years post-treatment making it one of most promising treatments available today for managing Type-2 Diabetes Mellitus (T2DM).
Fractyl Laboratories Inc.'s mission goes beyond just treating T2DM; they are committed towards improving overall health outcomes for people living with chronic metabolic diseases such as obesity and non-alcoholic fatty liver disease (NAFLD). They believe that by targeting key metabolic pathways like those found within duodenal mucosa they can help prevent progression towards more severe forms of these diseases while also improving quality-of-life outcomes for patients who suffer from them.
In conclusion, Fractyl Laboratories Inc.'s innovative approach towards treating T2DM through Revita DMR offers hope for millions worldwide who struggle daily with managing their condition effectively. Their commitment towards improving overall health outcomes makes them one-of-a-kind among biotech companies working on similar projects today - truly setting them apart from others!